{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T09:03:55Z","timestamp":1794128635853,"version":"4.8.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jacl.2014.03.004","type":"journal-article","created":{"date-parts":[[2014,4,29]],"date-time":"2014-04-29T08:16:51Z","timestamp":1398759411000},"page":"S58-S71","source":"Crossref","is-referenced-by-count":417,"special_numbering":"S","title":["An assessment by the Statin Muscle Safety Task Force: 2014 update"],"prefix":"10.1016","volume":"8","author":[{"given":"Robert S.","family":"Rosenson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven K.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry A.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2014.03.004_bib1","unstructured":"Stone NJ, Robinson J, Lichtenstein AH, et\u00a0al. 2013 ACC\/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, in press."},{"key":"10.1016\/j.jacl.2014.03.004_bib2","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2014.03.004_bib3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.03.004_bib4","doi-asserted-by":"crossref","first-page":"69C","DOI":"10.1016\/j.amjcard.2005.12.013","article-title":"An assessment of statin safety by muscle experts","volume":"97","author":"Thompson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib5","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/S0735-1097(02)02030-2","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"40","author":"Pasternak","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib6","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cjca.2011.05.007","article-title":"Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference","volume":"27","author":"Mancini","year":"2011","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib7","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1001\/jama.292.21.2585","article-title":"Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs","volume":"292","author":"Graham","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.03.004_bib8","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib9","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/archinte.166.11.1232-b","article-title":"Observations from a statin myopathy clinic","volume":"166","author":"Phillips","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2014.03.004_bib11","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1007\/s11606-008-0636-7","article-title":"Prevalence of musculoskeletal pain and statin use","volume":"23","author":"Buettner","year":"2008","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib12","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/mus.22205","article-title":"Prevalence and risk factors of muscle complications secondary to statins","volume":"44","author":"El-Salem","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2014.03.004_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2012.03.003","article-title":"Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users","volume":"6","author":"Cohen","year":"2012","journal-title":"J\u00a0Clin Lipidol"},{"key":"10.1016\/j.jacl.2014.03.004_bib14","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib15","doi-asserted-by":"crossref","unstructured":"Ganga HV, Slim HB, Thompson PD. Systematic review of\u00a0statin-induced muscle problems in clinical trials. Am Heart J. in press.","DOI":"10.1016\/j.ahj.2014.03.019"},{"key":"10.1016\/j.jacl.2014.03.004_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.amjmed.2008.08.033","article-title":"Relationship of ethnic origin, gender, and age to blood creatine kinase levels","volume":"122","author":"Neal","year":"2009","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib17","doi-asserted-by":"crossref","first-page":"526","DOI":"10.7326\/0003-4819-158-7-201304020-00004","article-title":"Discontinuation of statins in routine care settings: a cohort study","volume":"158","author":"Zhang","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ahj.2013.06.004","article-title":"Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience","volume":"166","author":"Mampuya","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2014.03.004_bib19","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.03.004_bib20","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib21","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2014.03.004_bib22","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/S0140-6736(10)60310-8","article-title":"Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial","volume":"376","author":"Armitage","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.03.004_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2014.03.004_bib24","first-page":"129","article-title":"Pain assessment: global use of the Brief Pain Inventory","volume":"23","author":"Cleeland","year":"1994","journal-title":"Ann Acad Med Singapore"},{"key":"10.1016\/j.jacl.2014.03.004_bib25","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/0304-3959(87)91074-8","article-title":"The short-form McGill Pain Questionnaire","volume":"30","author":"Melzack","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.jacl.2014.03.004_bib26","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jacl.2014.03.004_bib27","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2125.2003.02044.x","article-title":"Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems","volume":"57","author":"Sinzinger","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2014.03.004_bib28","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2014.03.004_bib29","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib30","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/mus.22236","article-title":"Statin-associated changes in skeletal muscle function and stress response after novel or accustomed exercise","volume":"44","author":"Meador","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2014.03.004_bib31","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JES.0b013e31826c169e","article-title":"Effect of statins on skeletal muscle: exercise, myopathy, and muscle outcomes","volume":"40","author":"Parker","year":"2012","journal-title":"Exerc Sport Sci Rev"},{"key":"10.1016\/j.jacl.2014.03.004_bib32","series-title":"Aids to the examination of the peripheral nervous system","year":"1976"},{"key":"10.1016\/j.jacl.2014.03.004_bib33","first-page":"104","article-title":"A randomized clinical trial to assess the effect of statins on skeletal muscle function and performance: rationale and study design","volume":"13","author":"Thompson","year":"2010","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib34","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/mus.21847","article-title":"Evaluation of skeletal muscle during calf exercise by 31-phosphorus magnetic resonance spectroscopy in patients on statin medications","volume":"43","author":"Wu","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2014.03.004_bib35","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1249\/MSS.0b013e3181aae96b","article-title":"Metabolic myopathies: functional evaluation by analysis of oxygen uptake kinetics","volume":"41","author":"Grassi","year":"2009","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.jacl.2014.03.004_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1017\/S0317167100007630","article-title":"Metabolic myopathies discovered during investigations of statin myopathy","volume":"35","author":"Baker","year":"2008","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.jacl.2014.03.004_bib37","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib38","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1002\/mus.22115","article-title":"Association of common variants in the human eyes shut ortholog (EYS) with statin-induced myopathy: evidence for additional functions of EYS","volume":"44","author":"Isackson","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2014.03.004_bib39","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1152\/japplphysiol.00361.2009","article-title":"CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage","volume":"108","author":"Hubal","year":"2010","journal-title":"J Appl Physiol (1985)"},{"key":"10.1016\/j.jacl.2014.03.004_bib40","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2014.03.004_bib41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mus.20567","article-title":"Genetic risk factors associated with lipid-lowering drug-induced myopathies","volume":"34","author":"Vladutiu","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2014.03.004_bib42","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMc0908215","article-title":"Neuromuscular symptoms and elevated creatine kinase after statin withdrawal","volume":"362","author":"Echaniz-Laguna","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2014.03.004_bib43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CND.0b013e3182852558","article-title":"Outcomes of statin myopathy after statin withdrawal","volume":"14","author":"Armour","year":"2013","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.jacl.2014.03.004_bib44","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/mus.23755","article-title":"Asymptomatic\/pauci-symptomatic creatine kinase elevations (hyperckemia)","volume":"47","author":"Silvestri","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jacl.2014.03.004_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1471-2474-13-100","article-title":"Selected statins produce rapid spinal motor neuron loss in\u00a0vitro","volume":"13","author":"Murinson","year":"2012","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.jacl.2014.03.004_bib46","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/17482960902870993","article-title":"Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice","volume":"10","author":"Iwamoto","year":"2009","journal-title":"Amyotroph Lateral Scler"},{"key":"10.1016\/j.jacl.2014.03.004_bib47","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.bbagen.2013.09.010","article-title":"Structural and functional characterization of simvastatin-induced myotoxicity in different skeletal muscles","volume":"1840","author":"Simsek Ozek","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jacl.2014.03.004_bib48","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.jacl.2014.03.004_bib49","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/ene.12174","article-title":"EFNS review on the role of muscle biopsy in the investigation of myalgia","volume":"20","author":"Kyriakides","year":"2013","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jacl.2014.03.004_bib50","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jacl.2014.03.004_bib51","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/FPC.0b013e328343dd7d","article-title":"Cerivastatin, genetic variants, and the risk of rhabdomyolysis","volume":"21","author":"Marciante","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.jacl.2014.03.004_bib52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.ahj.2013.01.025","article-title":"Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy","volume":"165","author":"Danik","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2014.03.004_bib53","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/tpj.2010.92","article-title":"Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin","volume":"12","author":"Brunham","year":"2012","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jacl.2014.03.004_bib54","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/sj.clpt.6100124","article-title":"Decreased skeletal muscle mitochondrial DNA in patients treated with high-dose simvastatin","volume":"81","author":"Schick","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2014.03.004_bib55","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2014.03.004_bib56","first-page":"297","article-title":"Efficacy and safety of atorvastatin 10 mg every other day in hypercholesterolemia","volume":"85","author":"Piamsomboon","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"10.1016\/j.jacl.2014.03.004_bib57","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.0197-3118.2005.04404.x","article-title":"Decreasing LDL cholesterol and medication cost with every-other-day statin therapy","volume":"8","author":"Juszczyk","year":"2005","journal-title":"Prev Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1345\/aph.1K604","article-title":"Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance","volume":"42","author":"Backes","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacl.2014.03.004_bib59","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.clinthera.2006.06.004","article-title":"Rosuvastatin 5 and 10 mg\/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies","volume":"28","author":"Glueck","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.jacl.2014.03.004_bib60","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.amjcard.2008.09.095","article-title":"Once-a-week rosuvastatin (2.5 to 20 mg) in patients with a previous statin intolerance","volume":"103","author":"Ruisinger","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib61","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.amjcard.2008.02.061","article-title":"Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins","volume":"101","author":"Gadarla","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib62","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2014.03.004_bib63","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/11584310-000000000-00000","article-title":"A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia","volume":"10","author":"Davidson","year":"2010","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2014.03.004_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.trsl.2008.11.002","article-title":"Low serum 25 (OH) vitamin D levels (<32 ng\/mL) are associated with reversible myositis-myalgia in statin-treated patients","volume":"153","author":"Ahmed","year":"2009","journal-title":"Transl Res"},{"key":"10.1016\/j.jacl.2014.03.004_bib65","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.atherosclerosis.2010.11.039","article-title":"The relationship of vitamin D deficiency to statin myopathy","volume":"215","author":"Gupta","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2014.03.004_bib66","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib67","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1139\/cjpp-2012-0118","article-title":"Coenzyme Q(10) and selenium in statin-associated myopathy treatment","volume":"91","author":"Fedacko","year":"2013","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.jacl.2014.03.004_bib68","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand Cardiovasc J"},{"key":"10.1016\/j.jacl.2014.03.004_bib69","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.jacl.2013.02.002","article-title":"A randomized trial of coenzyme Q10 in patients with statin myopathy: rationale and study design","volume":"7","author":"Parker","year":"2013","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2014.03.004_bib70","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.amjcard.2009.08.672","article-title":"Tolerability of red yeast rice (2,400 mg twice daily) versus pravastatin (20 mg twice daily) in patients with previous statin intolerance","volume":"105","author":"Halbert","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2014.03.004_bib71","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0025-6196(11)60897-5","article-title":"Toward \u201cpain-free\u201d statin prescribing: clinical algorithm for diagnosis and management of myalgia","volume":"83","author":"Jacobson","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacl.2014.03.004_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1517\/14740338.2011.540568","article-title":"Statin-induced myopathy: a review and update","volume":"10","author":"Abd","year":"2011","journal-title":"Expert Opin Drug Saf"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414001603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287414001603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T13:25:39Z","timestamp":1648905939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287414001603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":72,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S1933287414001603"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2014.03.004","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}